Company intelligence / Profile preview
Alvogen Korea
Seoul, South Korea
- Ownership
- Private
- Development stage
- Other
01
Overview
Alvogen Korea has approved drugs marketed in South Korea across a range of therapy areas, including the first locally approved biosimilar of bevacizumab (Alymsys) for oncology and sapropterin dihydrochloride (Diterin) for PKU. Its commercial-stage pipeline focuses on generics, biosimilars, and niche specialty drugs[2][4][9].
- Therapeutic areas
- EndocrinologyNephrologyMetabolic DisordersCardiovascularOncologyNeurology
- Modalities
- Small moleculeBiologicBiosimilar
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
VIVUS (Qsymia anti-obesity drug partnership)[6]Dipharma S.A. (exclusive distribution for Diterin in Korea)[4]
Beyond the preview
Go deeper on Alvogen Korea.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alvogen Korea.